Foam surfaces vs reactive foam and gel surfaces
All reported adverse events · pressure ulcer prevention
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
319 questions · 326 findings · 94 reviews
No studies found 89 · 27.3%GRADE not reported 19 · 5.8%Very low 89 · 27.3%Low 81 · 24.8%Moderate 40 · 12.3%High 8 · 2.5%
Foam surfaces vs alternating pressure (active) air surfaces
All reported adverse events · pressure ulcer prevention
1 finding from 1 review
- no estimate extracted3 studies · 2181 participantsVery low
Antidepressants vs placebo
Adverse events at 12 months · people with inflammatory bowel disease
Antidepressants showed no clear difference in adverse events at 12 months compared with placebo (low certainty).
1 finding from 1 review
- Adjuvant therapy with antidepressants for the management of inflammatory bowel disease 2019 · Cochrane Headline outcomes onlyRR 2.29 [0.78, 6.73]1 study · 26 participantsLow
Two infusions of natalizumab (300 mg or 3 mg/kg) vs placebo
Adverse events up to week 12 · Patients with active Crohn's disease
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.07 [0.92, 1.24]1 study · 129 participantsModerate
Two infusions of natalizumab (6 mg/kg) vs placebo
Adverse events up to week 12 · Patients with active Crohn's disease
Two infusions of natalizumab (6 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.97 [0.8, 1.17]1 study · 114 participantsModerate
Three infusions of natalizumab (300 mg) vs placebo
Adverse events up to week 12 · Patients with active Crohn's disease
Three infusions of natalizumab (300 mg) showed no clear difference in adverse events up to week 12 compared with placebo (high certainty).
1 finding from 1 review
- RR 1.03 [0.98, 1.08]2 studies · 1415 participantsHigh
Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab
Adverse events up to week 10 · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in adverse events up to week 10 compared with placebo and two infusions of infliximab (moderate certainty).
1 finding from 1 review
- RR 0.93 [0.85, 1.03]1 study · 79 participantsModerate
One infusion of natalizumab (300 mg or 3 mg/kg) vs placebo
Adverse events up to week 12 · Patients with active Crohn's disease
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.91 [0.75, 1.09]1 study · 131 participantsModerate
Massage vs active control
Adverse events Self‐reported · patients with LBP
1 finding from 1 review
- no estimate extracted5 studies · 585 participantsVery low
Massage vs inactive control
Adverse events Self‐reported · patients with LBP
1 finding from 1 review
- no estimate extracted4 studies · 624 participantsVery low
Inulin and oligofructose 15 g vs inulin and oligofructose 7.5 g daily
Total adverse events (9 weeks) · Patients with active mild to moderate ulcerative colitis
It is very uncertain whether inulin and oligofructose 15 g changes total adverse events (9 weeks) compared with inulin and oligofructose 7.5 g daily (very low certainty).
1 finding from 1 review
- Prebiotics for induction and maintenance of remission in ulcerative colitis 2024 · Cochrane Headline outcomes onlyRR 1.71 [0.72, 4.06]1 study · 31 participantsVery low
Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)
Side effects or other adverse events
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)
Side effects or other adverse events
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Berotralstat vs placebo or active control
Serious adverse events (during · children or adults with Types I or II HAE
Berotralstat showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).
1 finding from 1 review
- Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes onlyRR 0.77 [0.02, 24.03]3 studies · 128 participantsLow
C1 esterase inhibitor vs placebo or active control
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
1 finding from 1 review
- Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes onlyRR 0.34 [0.01, 8.14]1 study · 44 participantsVery low
Plasma‐derived C1 esterase inhibitor vs placebo or active control
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether plasma‐derived C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
1 finding from 1 review
- Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes onlyRR 0.54 [0.09, 3.1]1 study · 71 participantsVery low
Nanofiltered C1 esterase inhibitor vs placebo or active control
Serious adverse events (during · children or adults with Types I or II HAE
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Recombinant human C1 esterase inhibitor vs placebo or active control
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether recombinant human C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
1 finding from 1 review
- Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes onlyRR 1.5 [0.06, 34.66]1 study · 29 participantsVery low
Lanadelumab vs placebo or active control
Serious adverse events (during · children or adults with Types I or II HAE
Lanadelumab showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).
1 finding from 1 review
- Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes onlyRR 0.88 [0.08, 10.39]2 studies · 162 participantsLow
Video feedback vs no intervention or inactive alternative intervention
Adverse events: parental stress · parent‐child dyads (including foster or adoptive carers), where the child was aged between birth and four years 11 months (inclusive), and…
1 finding from 1 review
- Video feedback for parental sensitivity and attachment security in children under five years 2019 · Cochrane Headline outcomes onlyno estimate extracted8 studies · 537 participantsLow